Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy-Reference-Cited by-同舟云学术

Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy

Published:2007-09 Issue:3 Volume:67 Page:426-433
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Colao Annamaria,Di Sarno Antonella,Guerra Ermelinda,Pivonello Rosario,Cappabianca Paolo,Caranci Ferdinando,Elefante Andrea,Cavallo Luigi M.,Briganti Francesco,Cirillo Sossio,Lombardi Gaetano

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2265.2007.02905.x/fullpdf

Reference41 articles.

1. Advances in the Treatment of Prolactinomas

2. A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea

3. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline

4. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine

5. Treatment of macroprolactinoma with cabergoline: a study of 85 patients

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying prognostic predictors for postoperative pituitary neuroendocrine tumour recurrence: an integrated clinical, radiological, and immunohistochemistry assessment;British Journal of Neurosurgery;2024-08-06

2. Cardiometabolic effects of hypoprolactinemia;Reviews in Endocrine and Metabolic Disorders;2024-07-30

3. Clinical aspects of the plurihormonal pituitary adenoma formation;South Russian Journal of Therapeutic Practice;2024-06-25

4. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited;Archives of Medical Research;2023-12

5. Adenomi ipofisari o tumori neuroendocrini ipofisari: attualità e consenso;EMC - Neurologia;2023-12